# Vivaldi Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vivaldi-biosciences

- Industry: Pharmaceuticals
- Headquarters: New York, US
- Website: www.vivaldibiosciences.com
- Total disclosed funding: $21M
- Latest round: Series A (Jan 8, 2009)
- Investors on record: 4

## About

Vivaldi Biosciences, Inc. is focused on developing innovative vaccines for viral respiratory diseases, utilizing their unique Delta NS1 technology to create self-adjuvanting vaccines for influenza and COVID-19.Vivaldi Biosciences, Inc. specializes in vaccine development for viral respiratory diseases, notably employing its proprietary Delta NS1 technology platform. The company is headquartered in New York, US. Bill Wick serves as the CEO. Vivaldi has raised a total of USD 18.85 mn, with its latest funding round, Series A, securing USD 18.85 mn from investors including Alexandria Venture Investments and Bay City Capital, among others. There have been four total funding deals, with the most recent occurring on July 8, 2010.Vivaldi Biosciences specializes in the development of innovative vaccines targeting viral respiratory diseases, with a focus on their proprietary Delta NS1 technology platform. Delta NS1 serves as a replication-deficient vaccine vector derived from a genetically modified, attenuated influenza virus strain. This platform enables the creation of broadly protective, self-adjuvanting vaccines that can be administered via nasal spray, with particular applications in combating influenza and COVID-19. The vaccines are designed to rapidly induce interferon, a key immune signaling protein, which enhances protective immunity against circulating viruses. Currently, Vivaldi's products aim to address global health challenges by providing solutions for both epidemic and pandemic scenarios, particularly within North America and Europe, where respiratory viral infections pose significant public health threats.Vivaldi Biosciences operates within a framework that emphasizes collaborative partnerships and clinical trials to advance its vaccine offerings. The company's revenue model incorporates funding from partnerships with research institutions and health organizations, as well as potential future revenue from commercial sales of vaccines upon regulatory approval. Transactions primarily involve agreements for clinical research and development that may lead to licensing opportunities for their flagship Delta NS1-based vaccines, including the DeltaFLU universal influenza vaccine and the Delta-19 COVID-19 and universal influenza combination vaccine. Pricing structures are anticipated to be aligned with industry standards for innovative vaccine products, involving agreements with public health agencies and private healthcare providers for distribution in various markets.Vivaldi Biosciences plans to leverage its recent funding of USD 18.85 mn from the Series A round to enhance its vaccine development efforts. The company aims to design and launch new products targeting respiratory diseases, with an emphasis on expanding into North America and Europe by 2025. Their strategy includes advancing the DeltaFLU and Delta-19 vaccines through clinical trials to secure regulatory approvals and subsequent commercialization.

## Funding rounds

- Series A, Jan 8, 2009, $19M — Alexandria Venture Investments, NGN Capital, Bay City Capital, Partnership Fund for New York City
- Series A, May 18, 2007, $2M — Bay City Capital

## Investors

- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- NGN Capital (https://capitalatlas.ai/funds/ngn-capital) — Series A
- Partnership Fund for New York City (https://capitalatlas.ai/funds/partnership-fund-for-new-york-city) — Series A